We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Annexin I Modulates Inflammatory Response

By Biotechdaily staff writers
Posted on 28 Jun 2005
Researchers studying how the immune system works have found that the anti-inflammatory protein annexin 1 protects the individual from the detrimental effects of severe inflammatory response syndrome (SIRS).

Investigators at Barts and the London, Queen Mary's School of Medicine and Dentistry (UK), developed a line of mice lacking the gene for annexin 1. More...
They challenged these animals with bacterial lipopolysaccharide (LPS) toxin and compared the response of their immune systems to that of normal mice.

Results published in the June 2005 issue of the American Journal of Pathology revealed that in normal animals the annexin 1 gene was activated as early as 90 minutes after LPS administration, with levels returning to normal by 24 hours. In contrast, administration of LPS to annexin 1-deficient mice produced a toxic response characterized by organ injury and death within 48 hours. The toxic response could be reversed by injections of low doses of annexin 1.

Senior author, Dr. Mauro Perretti, professor of biochemical pharmacology at Barts and the London, Queen Mary's School of Medicine and Dentistry, said, "For too long, we have ignored anti-inflammatory/counter-regulatory mediators and the impact they have on pathology outcome; studying the way our body controls responses to infections can allow the modeling of new therapeutics with lower side effects.”





Related Links:
Queen Mary's School of Medicine

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Aspiration System
VACUSAFE
New
Automatic CLIA Analyzer
Shine i6000
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.